NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

What Happened

• NeuroOne Medical Technologies Corp. (NMTC) announced that Chief Financial Officer Ronald McClurg notified the company on April 24, 2026 of his intention to retire as CFO effective June 30, 2026. He will remain employed as a Senior Advisor through December 31, 2026 to support the transition.
• The Board appointed Chief Operating Officer Christopher Volker to succeed Mr. McClurg as CFO effective July 1, 2026. Mr. Volker has senior medtech experience (Abbott, Cardiovascular Systems, Inc., St. Jude Medical), a Wharton MBA, and holds the Chartered Financial Analyst® designation.

Key Details

• Ronald McClurg’s retirement as CFO is effective June 30, 2026; he will serve as Senior Advisor until December 31, 2026.
• Christopher Volker’s base salary will be increased to $350,000 upon becoming CFO; other material employment terms remain unchanged.
• The company and Mr. McClurg entered a Transition and Release Agreement dated April 28, 2026, under which he will continue to receive his current salary and benefits through the Retirement Date and provide a general release and customary restrictive covenants. The agreement is filed as Exhibit 10.1.

Why It Matters

• This is a scheduled executive transition that updates NeuroOne’s finance leadership and maintains continuity through an internal promotion and a planned advisory period for the outgoing CFO. Investors should note the effective dates, the modest increase in base pay for the incoming CFO, and the existence of a formal transition agreement that governs post-retirement compensation and restrictive covenants.